Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 52 Publications

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 MmnIT4lv[XOnIFHzd4F6 Mmr3TY5pcWKrdHnvckBw\iCSRFfGMYlv\HWlZXSgRpJlXSCrbnPvdpBwemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwO{DPxE1? NHfqdZkyOjZ2NkCxPS=>
3T3 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVezVoZUUW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhcW6mdXPl[EA{XDNiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjBzIN88US=> M3T5UlEzPjR4MEG5
3T3 MWDGeY5kfGmxbjDBd5NigQ>? NXzLcZVKUW6qaXLpeIlwdiCxZjDWZZNkfWyjcjDlcoRwfGinbHnhcEBoem:5dHig[oFkfG:{IILlZ4VxfG:{IIfpeIghUUN3MDDv[kAxNjB3IN88US=> M1Ww[VEzPjR4MEG5
3T3 NVHyVlRbU2mwYYPlJGF{e2G7 NFvJ[IwzOCCvaX6= NX7r[YtTTE2VTx?= NUjPVWRoS2WubIXsZZIhcW6qaXLpeIlwdiCxZjDWSWdHKGmwZIXj[YQhcHWvYX6gT2RTKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNlIh|ryP MkHvNVYyPjJyMEi=
NIH3T3 NIO5T4FMcW6jc3WgRZN{[Xl? NFHGVVczOCCvaX6= M{HPPGROW09? MlXabY5pcWKrdDDoeY1idiCNRGKgb4lv[XOnIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yMUig{txO NGXidmYyPjF4MkCwPC=>
A549 NVnLV5lqTnWwY4Tpc44hSXO|YYm= NXjaTJdVTE2VTx?= NYDTUWNMUW6qaXLpeIlwdiCxZjDjMW1mfCCmZYDlcoRmdnRiSFfGMYlv\HWlZXSgbJVu[W5iQUW0PUBk\WyuIH3p[5JifGmxbjD3bZRpKEmFNUCgc4YhOiEQvF2= NEHscGcyQDR|NEG0OS=>
DU145 MX7GeY5kfGmxbjDBd5NigQ>? MU\EUXNQ NYO3bpM5UW6qaXLpeIlwdiCxZjDjMW1mfCCmZYDlcoRmdnRiSFfGMYlv\HWlZXSgbJVu[W5iRGWxOFUh[2WubDDzZ4F1fGW{aX7nJJdqfGhiSVO1NEBw\iBzMDFOwG0> NH3EcWIyQDR|NEG0OS=>
KB3-1 NHjMcHhEgXSxdH;4bYMhSXO|YYm= MVu3NkBp MlX2SG1UVw>? MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQMYdxNW6nZ3H0bZZmKEuELUOtNUBk\WyuczD3bZRpKEmFNUCgc4YhOi5|IN88US=> NEfUc|EyQTN7N{OyNi=>
KBV1 NXHwcXlES3m2b4TvfIlkKEG|c3H5 NVv1NHVKPzJiaB?= NFj5SXNFVVOR NF\kOmNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRNWeueXPvdJJwfGWrbj3lfJBz\XO|aX7nJGtDXjFiY3XscJMhf2m2aDDJR|UxKG:oIESuNUDPxE1? NUDZUlJ7OTl|OUezNlI>
A375 NFLJXndEgXSxdH;4bYMhSXO|YYm= M1;xS|czKGh? NGHSbIpFVVOR NUns[pFqUUN3ME21MlQh|ryP NGrNUYsyQTZ3NESwPC=>
RS4-11 M1;l[2Z2dmO2aX;uJGF{e2G7 MUOyJIg> MnzuTY5pcWKrdHnvckBw\iCITGSzJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFA6QSEQvF2= NVLhZo1mOTl4NUS0NFg>
RS4-11 M4DncmZ2dmO2aX;uJGF{e2G7 MlX6NkBp MVXJcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{PCEQvF2= MWGxPVY2PDRyOB?=
Sf9 M1HMc2tqdmG|ZTDBd5NigQ>? NVjmdGV{OzBibXnu MYfJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiVlXHSnIh\XiycnXzd4VlKHerdHigTWM2OCCxZjCwMlE5PSEQvF2= MlnCNVk5PTRyNUG=
Ba/F3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSzNWpyPzJiaB?= MofpTWM2OD1zLkKg{txO M1PYTFIxOTF5MEC0
BaPTC2 NWnDeVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYK3NkBp Mnr2TWM2OD1yLkKyJO69VQ>? M3W5TFIxOTF5MEC0
Sf9 NWrEZWN5TnWwY4Tpc44hSXO|YYm= MmCzNUBp NWXGSlVtTE2VTx?= MoTFTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKaYOteIFo\2WmIGLFWEBmgHC{ZYPz[YQhf2m2aDDJR|UxKG:oIEGuN{DPxE1? Mnu2NlAyOTdyMES=
H4 M1v5e2N6fG:2b4jpZ{BCe3OjeR?= M2rJWlExKM7:TR?= MnywWI95cWOrdImgbY4hcHWvYX6gTFQh[2WubIO= M4nEc|IxOzVyOEC2
SF-539 NFTpc45McW6jc3WgRZN{[Xl? MYizN|Mh|ryP MUS2NEBucW5? MnG4SG1UVw>? MWXJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGyMlIh|ryP NEDIeJozODRyM{ewNC=>
U251 M2jFNGtqdmG|ZTDBd5NigQ>? MXGzN|Mh|ryP M2DRUFYxKG2rbh?= MXHEUXNQ MnHhTY5pcWKrdHnvckBw\iCYRVfGVlIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzOD65JO69VQ>? NVnpXVNsOjB2MEO3NFA>
A431 M4jVU2tqdmG|ZTDBd5NigQ>? M3HpZmlvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOTJwMjFOwG0> Mm\aNlA2PThyN{K=
A431 NETOVYxMcW6jc3WgRZN{[Xl? Mnf6TY5pcWKrdHnvckBw\iCYRVfGVlIh\XiycnXzd4VlKHerdHigTWM2OCCxZjCxPE46KM7:TR?= MWmyNFU2QDB5Mh?=
HepG2 NIKyVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzrO|IhcA>? NFHjWnFKSzVyPUOuPFEh|ryP NFXyWHczODV5MEWyOi=>
Kasumi-1 M3nRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzjbJZIPzJiaB?= MkDzTWM2OD1yLkCxOkDPxE1? MYOyNFU4ODV{Nh?=
RS4-11 M3L3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L4[lczKGh? M1\GeGlEPTB;MTFOwG0> NYLzcphPOjB3N{C1NlY>
THP1 NU\oZZg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXq3NkBp M4j5OWlEPTB;MD61JO69VQ>? NYOzOXlkOjB3N{C1NlY>
Kasumi-1 M2fuSWZ2dmO2aX;uJGF{e2G7 NIS5dnlKdmirYnn0bY9vKG:oIHOtT4l1KGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODF3IN88US=> Ml\1NlA5OzNyM{m=
A549 M4fVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFK0NYoyPiCq MoqxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\Wyucx?= MmG5NlE1PTB2NkO=
HL60 NIPxNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUexOkBp MYrBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy| Mnu1NlE1PTB2NkO=
HUVEC M4LRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vrcVE3KGh? NECycHFKdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIEKuO|Uh|ryP MnnXNlE1PTB2NkO=
HUVEC MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETSe|QyPiCq MXPJcohq[mm2aX;uJI9nKGKIR1[tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDRwMESg{txO MmPINlE1PTB2NkO=
IM9 M4HvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC1NVYhcA>? NIqwVIlCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDJUVkh[2WubIO= Mn;5NlE1PTB2NkO=
K562 M1TCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;qNVYhcA>? NICyPYdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzz M2HQNVIyPDVyNE[z
MDA-MB-231 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3WySlE3KGh? NWi2[o5DSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\Wyucx?= MmLBNlE1PTB2NkO=
H460 NUXLbZZuS3m2b4TvfIlkKEG|c3H5 NHLtW3Y4OiCq MkfhTWM2OD1{Lkeg{txO M2XiV|IyPjJzOEiw
SMMC7721 NWfm[m52S3m2b4TvfIlkKEG|c3H5 NXLCOI1sPzJiaB?= M1vV[2lEPTB;Nj60O{DPxE1? M3jwSlIyPjJzOEiw
WI38 Mo[1R5l1d3SxeHnjJGF{e2G7 NXXuOWxpPzJiaB?= NYiwe|RZUUN3ME24MlU3KM7:TR?= MV[yNVYzOTh6MB?=
HEK293 M1qwN2tqdmG|ZTDBd5NigQ>? M1XHZlExOCCwTR?= MnLhNUBp NWf3OIo4\G:nczDuc5QhcW6qaXLpeEBXTUeILXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kB1gXKxc3nu[UAyOTd3IILld4llfWVib36gWmVITlJ{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHN? MlHpNlE5QDV{OEe=
HUVEC MWjGeY5kfGmxbjDBd5NigQ>? NIDLcGwyKM7:TR?= MlnGNlQhcA>? NXnaVVlnSW62aXHu[4lw\2WwaXOgZYN1cX[rdImgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iVlXHSk1qdmS3Y3XkJINmdGxibXnndoF1cW:w Mk\wNlE6PjN|MEW=
HUVEC M{nL[WZ2dmO2aX;uJGF{e2G7 MkL1NUDPxE1? MUKxJIg> M4XCVGlvcGmkaYTpc44hd2ZiRWLLJJBpd3OyaH;yfYxifGmxbjDheEBVcHJ{MEKvWJlzOjB2IHnuJHZGT0Zvc4TpcZVt[XSnZDDIWXZGSw>? MmfPNlE6PjN|MEW=
HUVEC NWDwVplrTnWwY4Tpc44hSXO|YYm= MkXPNUDPxE1? MlfPNUBp NIf6R3JKdmirYnn0bY9vKG:oIHXOU3MheGixc4Doc5J6dGG2aX;uJIF1KFOncj2xNVczKGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> MVuyNVk3OzNyNR?=
HUVEC NXTmZmVjU2mwYYPlJGF{e2G7 Mlz0NUDPxE1? NEPOZ3oyKGh? NVPwcXlHUW6qaXLpeIlwdiCxZjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGG2IIT5dk0yOTd3IHnuJHZGT0Zvc4TpcZVt[XSnZDDIWXZGSw>? NIT5U5czOTl4M{OwOS=>
HUVEC M1iyOmZ2dmO2aX;uJGF{e2G7 MkC5NUDPxE1? MlTTNUBp MWPkc4V{KG6xdDDpcohq[mm2IFHLWEBxcG:|cHjvdplt[XSrb36gZZQhW2W{LUS3N{BqdiCYRVfGMZN1cW23bHH0[YQhUFWYRVO= NULobHpsOjF7NkOzNFU>
HL60 MVjDfZRwfG:6aXOgRZN{[Xl? MmjFOVAh|ryP MnXBOFghcA>? NUH5TZV4TE2VTx?= NUezfHBqUUN3ME2xOU42KM7:TR?= MV[yNlAyQTF6OB?=
K562 M17hUWN6fG:2b4jpZ{BCe3OjeR?= NHrtcnI2OCEQvF2= Ml;DOFghcA>? NWP0UXJZTE2VTx?= NYCzUVVNUUN3ME2yNU46KM7:TR?= NF6yUYozOjBzOUG4PC=>
PC3 M1XJXGN6fG:2b4jpZ{BCe3OjeR?= NFLOdnE2OCEQvF2= MXm0PEBp M1LkbWROW09? M2HWeWlEPTB;MkWuNUDPxE1? MkPONlIxOTlzOEi=
SF-539 MorNT4lv[XOnIFHzd4F6 MVWzN|Mh|ryP M3XwO|YxKG2rbh?= NH3nN2RKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTD0fZJwe2mwZTDrbY5ie2ViYXP0bZZqfHliaX6gVGRITi2EQj3zeIlufWyjdHXkJIh2dWGwIGPGMVU{QSClZXzsd{B4cXSqIFnDOVAhd2ZiMUKuNkDPxE1? NEe0fFAzOjJyNEe0NS=>
HAEC MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXexNFAh|ryP NUjvS25vPzJiaB?= NUXhfYVtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIRWVEKGOnbHzzJIV5eHKnc4PpcochXkWJRmKge4l1cCCLQ{WwJI9nKDBwMTFOwG0> MX2yNlQ1PDZ5OR?=
HT-29 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvLR2MyODBizszN MWi3NkBp NVfRXnBOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BmgHC{ZYPzbY5oKF[HR1\SJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>? M1\lZlIzPDR2Nke5
MV4-11 MlzOR5l1d3SxeHnjJGF{e2G7 MYm3NkBp MV\JR|UxRTBwMECzJO69VQ>? MWqyNlQ2OjVzOB?=
HepG2 M2PpS2N6fG:2b4jpZ{BCe3OjeR?= MV60PEBp NIL5XnhKSzVyPUGzMlI1KM7:TR?= MnPBNlI1QDN4MEi=
PC9 MlfvR5l1d3SxeHnjJGF{e2G7 MYq0PEBp M3Xl[mlEPTB;MUCuPVch|ryP MlS1NlI1QDN4MEi=
CAKI-1 MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxNFAh|ryP NHX0WVE1QCCq M4fSNGROW09? M{TmV2dKPTB;MD62N{DPxE1? MYmyNlU3ODZ{Nx?=
EKVX MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\pfWhFOTByIN88US=> MYK0PEBp M1Oze2ROW09? M{LnNmdKPTB;Nz65JO69VQ>? NVzBWndzOjJ3NkC2Nlc>
MCF7 MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfLdpYyODBizszN M3TuelQ5KGh? NHHvPHFFVVOR MkjCS2k2OT1{IN88US=> NWfZS2pwOjJ3NkC2Nlc>
MDA-MB-435 M3job2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXnNVAxKM7:TR?= M{W2SFQ5KGh? MVXEUXNQ M1:3b2dKPTJ;MjFOwG0> NV7wOZJoOjJ3NkC2Nlc>
OVCAR3 M2jPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[xNFAh|ryP MXG0PEBp MV;EUXNQ MnfxS2k2Oz1|LkKg{txO NIPMXGczOjV4ME[yOy=>
SNB19 NWnQOml4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mly4NVAxKM7:TR?= NIrHe4c1QCCq MXnEUXNQ MmrGS2k2PD1zMDFOwG0> MWWyNlU3ODZ{Nx?=
SW620 M1\4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ZNVAxKM7:TR?= M1LPelQ5KGh? M{TlVWROW09? MkX1S2k2PT1zLkOg{txO M1PK[VIzPTZyNkK3
TK10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjST|FDOTByIN88US=> NWHrWHg6PDhiaB?= Ml62SG1UVw>? MYXHTVU3RTZwMzFOwG0> NEPPcGYzOjV4ME[yOy=>
UACC257 MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L2NlExOCEQvF2= MV60PEBp NYeydo1bTE2VTx?= NFiyVlNIUTV5PUSg{txO M4jMcFIzPTZyNkK3
HAEC MVfDfZRwfG:6aXOgRZN{[Xl? MmDCNVAxKM7:TR?= MoHqO|IhcA>? NVi4U5FQTE2VTx?= NUPOc5dlS3m2b4TvfIlkcXS7IHHnZYlve3RiVlXHSnIh\XiycnXzd4lv\yCKQVXDJJdqfGhiSVO1NEBw\iByLkGg{txO NHLETHQzOzF|MUW0NS=>
HT-29 NF7oXG9EgXSxdH;4bYMhSXO|YYm= NVPldm9VOTByIN88US=> MYK3NkBp MW\EUXNQ MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBXTUeIUjDlfJBz\XO|aX7nJIh2dWGwIFjUMVI6KGOnbHzzJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>? MlixNlMyOzF3NEG=
HCT116 MnLOSpVv[3Srb36gRZN{[Xl? NXS3fVNbOjRiaB?= M4\TU2ROW09? MljERY51cW2rZ4LheI9zgSCjY4Tpeol1gSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygcYloemG2aX;u MV2yN|E2OzJyMB?=
HUVEC MWfGeY5kfGmxbjDBd5NigQ>? MVSyJO69VQ>? MXGxPEBp MljrSG1UVw>? NIPmb4hCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQ4OgeY5l\XJiaInwc5hq[yClb37kbZRqd25iYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dXLlJIZwem2jdHnvci=> NFvzSXMzOzF3M{KwNC=>
ACHN MmL4R5l1d3SxeHnjJGF{e2G7 M{LhXVYh\A>? MVHJR|UxRTJwNTFOwG0> MVOyN|M3ODFyNB?=
A498 M2PnR2N6fG:2b4jpZ{BCe3OjeR?= MmTtNVAxKM7:TR?= NGfIbZU4OiCq NVn0U2FlTE2VTx?= MUjJR|UxRTRwMzFOwG0> NXLZUZBVOjN2OEm2NlY>
HUVEC M3zqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[4OVMh|ryP NUO1Z2dwOjRiaB?= M1LGdWROW09? NYHzVnNZSW62aXHu[4lw\2WwaXOgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQhfHWkZTDmc5Ju[XSrb36ge4l1cCCHQ{WwJI9nKDBwNkS1JO69VQ>? M4\RZVI{PTh|OUGx
HUVEC NUSybm5CU2mwYYPlJGF{e2G7 MnLjNlAxKM7:TR?= M33kO2ROW09? MYnJcohq[mm2aX;uJI9nKF[HR1\SNkBxcG:|cHjvdplt[XSrb36gbY4h\3Kxd4ToJIZi[3Sxcj3zeIlufWyjdHXkJGhWXkWF NH[4eVIzOzV6M{mxNS=>
HUVEC NVzsTlRGU2mwYYPlJGF{e2G7 Moj0NlAxKM7:TR?= M3LTc2ROW09? NHvNW4xKdmirYnn0bY9vKG:oIG\FS2ZTOSCyaH;zdIhwenmuYYTpc44hcW5iZ4Lve5RpKG[jY4Tvdk1{fGmvdXzheIVlKEiXVlXD MkDENlM2QDN7MUG=
A549 MXHDfZRwfG:6aXOgRZN{[Xl? M4CzOFczKGh? NXjNe|lOTE2VTx?= MlzqTWM2OD1{LkS0JO69VQ>? MWWyN|YxOjR2MR?=
HCT116 MWrDfZRwfG:6aXOgRZN{[Xl? NH;wW5A4OiCq MXjEUXNQ NH;4UZhKSzVyPUSuO|Eh|ryP MoDZNlM3ODJ2NEG=
MCF7 M2DJdmN6fG:2b4jpZ{BCe3OjeR?= MkG4O|IhcA>? NVfBfldvTE2VTx?= NIHYZWxKSzVyPU[uNlkh|ryP NHT5blczOzZyMkS0NS=>
BGC Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnnN3I{PzJiaB?= NIXk[W9FVVOR NGTpTVdKSzVyPUSuO|gh|ryP NGjneGgzOzl7OUC0NC=>
BxPC3 NFXzbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TNXFczKGh? MkTJSG1UVw>? MojDTWM2OD1|Lk[zJO69VQ>? NETufWYzOzl7OUC0NC=>
HT-29 M2PZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjVbHE4OiCq NVSxeIwxTE2VTx?= NUjUdW8zUUN3ME2xMlQ4KM7:TR?= Mkf0NlM6QTlyNEC=
T24 NXSxS3BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDZSWo4OiCq MXLEUXNQ MVTJR|UxRTJwNESg{txO Ml;QNlM6QTlyNEC=
4T1 MoPaR5l1d3SxeHnjJGF{e2G7 MVS3NkBp MnzXSG1UVw>? NEjoTodKSzVyPUCuNFE3KM7:TR?= NGexb|gzPDh7ME[1Ni=>
MCF7 MYnDfZRwfG:6aXOgRZN{[Xl? NHLpR|Y4OiCq MVjEUXNQ NGTKeFRKSzVyPUCuNFI4OSEQvF2= MWGyOFg6ODZ3Mh?=
MCF7 NVvBVXk6S3m2b4TvfIlkKEG|c3H5 MVO3NkBp NF[zV3BFVVOR MonNTWM2OD1yLkCyPVMh|ryP Mn3rNlQ5QTB4NUK=
MDA-MB-231 MoDZR5l1d3SxeHnjJGF{e2G7 M{LETFczKGh? M3e2RmROW09? M3v2V2lEPTB;MD6wNlI{KM7:TR?= NGDv[5YzPDh7ME[1Ni=>
MDA-MB-435 MXHDfZRwfG:6aXOgRZN{[Xl? MWG3NkBp NXvtfWw4TE2VTx?= MkT6TWM2OD1yLkCwPVch|ryP NX23eG1rOjR6OUC2OVI>
MDA-MB-468 MWTDfZRwfG:6aXOgRZN{[Xl? MXS3NkBp NYHCT3NyTE2VTx?= MWjJR|UxRTBwMEC2NUDPxE1? NYnMRoVPOjR6OUC2OVI>
A431 MojBT4lv[XOnIFHzd4F6 MYCxNEDPxE1? NXTiTJpJOSCq NFnKeYJFVVOR NH\zSVVKdmirYnn0bY9vKG:oIFXHSnIhf2m2aDDJR|UxKG:oIECuNVczOSEQvF2= MnP0NlQ5QTB4NUK=
SH-SY5Y M3H1SmtqdmG|ZTDBd5NigQ>? M1H2clExKM7:TR?= MYGxJIg> M1OwTGROW09? M2fs[GlvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIIfpeIghUUN3MDDv[kAxNjB6M{Gg{txO NGjG[lMzPDh7ME[1Ni=>
U251 NWPRTHA5U2mwYYPlJGF{e2G7 M3jORVExKM7:TR?= NX3qSZVsOSCq MXXEUXNQ M3PqdmlvcGmkaYTpc44hd2ZiVlXHSnIzKHerdHigTWM2OCCxZjCwMlAyQDlizszN MoLiNlQ5QTB4NUK=
Bel7402 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYm3NkBp NYO3SmRsTE2VTx?= M{\ISWlEPTB;Mj62O{DPxE1? MlGxNlQ6ODR7NkG=
HK2 NYfXSotwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\sO|IhcA>? NWfBPWMyTE2VTx?= NUXMUVFiUUN3ME21Mlg2KM7:TR?= NILVU2QzPDlyNEm2NS=>
LO2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmriO|IhcA>? Mo\HSG1UVw>? MmXaTWM2OD1zOT65N{DPxE1? NX3yUHBPOjR7MES5OlE>
MV4-11 NHvMdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17BZVQ5KGh? M1nKfGROW09? M{LMXmlEPTB;MD6wNFMh|ryP M1u2XVI1QTB2OU[x
NCI-H3122 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfwO|IhcA>? M374UmROW09? MkjGTWM2OD1yLkizJO69VQ>? MYqyOFkxPDl4MR?=
NCI-H460 NFHJeYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPqTG5[PzJiaB?= NH\KN4xFVVOR NWW3eXRCUUN3ME20MlMyKM7:TR?= NH3GZ3kzPDlyNEm2NS=>
NCI-H526 NGe2SJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\GOmI4OiCq NHXhfoRFVVOR M4TSfGlEPTB;MT6wNUDPxE1? M1y1NlI1QTB2OU[x
TT MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfubI84OiCq MmexSG1UVw>? M4jiRmlEPTB;MD6wOEDPxE1? M2DUTVI1QTB2OU[x
EoL-1-cell M3;LXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1SxW2lEPTB;MT62OEBxVQ>? MkHoV2FPT0WU
MV-4-11 NYnZTXZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X0OWlEPTB;MkeyJJBO MWTTRW5ITVJ?
NOS-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHjUnJKSzVyPUG1MlMhdk1? NWLJe4l7W0GQR1XS
CGTH-W-1 NFq5fnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fV[GlEPTB;M{CuPVQhdk1? MYDTRW5ITVJ?
MONO-MAC-6 NY\nW45uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHQR49KSzVyPUOzMlghdk1? NGfnVYRUSU6JRWK=
ALL-PO Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDaTWM2OD15OT64PUBvVQ>? NHfCWpBUSU6JRWK=
NKM-1 M3vHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHWTWM2OD17OD61NkBvVQ>? NUe2Z2VsW0GQR1XS
KM12 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jIbGlEPTB;M{WwMlE1KG6P MVPTRW5ITVJ?
TE-15 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETVd4xKSzVyPUWwO{43OSCwTR?= MYDTRW5ITVJ?
697 M4LVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK1TWM2OD14MUSuNlUhdk1? M3vKVHNCVkeHUh?=
MOLT-16 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLMWGxKSzVyPU[zNU4{OiCwTR?= M3\SNXNCVkeHUh?=
GB-1 M{DWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK2TWM2OD15MUCuNlMhdk1? Ml;vV2FPT0WU
TE-12 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzMcFR5UUN3ME24NFQvPTVibl2= MVTTRW5ITVJ?
ES6 MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;nTWM2OD17OEGuNFYhdk1? NX32UYd7W0GQR1XS
LC-2-ad NEHLW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SyR2lEPTB;MT6xNVQxPyEQvF2= MUPTRW5ITVJ?
BL-70 M2ftTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfQTWM2OD1zLkGxPFQ3KM7:TR?= MoXmV2FPT0WU
ETK-1 M1ewR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfvUnNKSzVyPUGuNlg2QCEQvF2= Mn2zV2FPT0WU
A4-Fuk NHzrXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXadllKSzVyPUGuN|QyPDFizszN NXnhbYNTW0GQR1XS
OCI-AML2 NXPN[|RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\qTWlEPTB;MT6zOlg2OSEQvF2= MojWV2FPT0WU
SIG-M5 NF3jUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjGTWM2OD1zLkO3NFA6KM7:TR?= M2GwPHNCVkeHUh?=
NCI-SNU-16 M{L4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj1XWZQUUN3ME2xMlQ3PDh4IN88US=> NU\mW2c4W0GQR1XS
PSN1 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFwNUC2O|Yh|ryP M1i3bXNCVkeHUh?=
SR NX7MeIpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HyPWlEPTB;MT61OFU4OiEQvF2= NWrOTYhEW0GQR1XS
A3-KAW NH\DZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\NTWM2OD1zLk[yOVQ3KM7:TR?= MkWwV2FPT0WU
KS-1 M2jiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfS[4QyUUN3ME2xMlY6OjR5IN88US=> NVnQNIdkW0GQR1XS
CTV-1 NIL0XWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwN{K3OVEh|ryP M2nxW3NCVkeHUh?=
LB1047-RCC MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTFwOEG2NlQh|ryP MoDHV2FPT0WU
EMG-01 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\iRmlEPTB;MT64N|U3OyEQvF2= NWraUHY1W0GQR1XS
TE-11 M{fRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHaTWM2OD1zLkizPVg2KM7:TR?= NYjCOYRiW0GQR1XS
CMK Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\pOYtQUUN3ME2xMlk2PTF5IN88US=> NI\YT2JUSU6JRWK=
NB1 M1rGN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r5dWlEPTB;MT65OlEyPyEQvF2= MVnTRW5ITVJ?
HAL-01 NGTFUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX0TWM2OD1{LkC1PVQ3KM7:TR?= NEKwR2tUSU6JRWK=
DEL MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPwUpFKSzVyPUKuNFg1QDJizszN NV;jS3FWW0GQR1XS
RL95-2 M{nKeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK3XYtYUUN3ME2yMlEyOTN5IN88US=> M{e2UHNCVkeHUh?=
KARPAS-299 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\iOJdKSzVyPUKuNVE{OTNizszN M1SxbXNCVkeHUh?=
EW-16 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULZ[3BNUUN3ME2yMlE{PTB6IN88US=> NUXIb4hnW0GQR1XS
RS4-11 NULkfYFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTBemhQUUN3ME2yMlE4QTJ2IN88US=> NHHUVHBUSU6JRWK=
BB30-HNC M4nJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTLTWM2OD1{LkKyN|c2KM7:TR?= NE\IXllUSU6JRWK=
DOHH-2 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjCUlltUUN3ME2yMlM{PDNzIN88US=> NETQOJlUSU6JRWK=
RPMI-8402 NUPYT4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnDTWM2OD1{LkOzOlE5KM7:TR?= NGDaR2hUSU6JRWK=
BV-173 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETM[oFKSzVyPUKuN|M3PiEQvF2= NFOz[ndUSU6JRWK=
TE-10 NVTGe|JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnzTWM2OD1{LkO0N|g1KM7:TR?= MmHqV2FPT0WU
TE-8 M1TNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJwM{ewN|gh|ryP NEK5cm5USU6JRWK=
K052 M{DFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X4S2lEPTB;Mj60NFIxOiEQvF2= NXLxS|BoW0GQR1XS
KARPAS-45 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDYTWM2OD1{LkS5OFQ3KM7:TR?= M1LVOXNCVkeHUh?=
SK-NEP-1 NHiwNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnVNZBKSzVyPUKuOlAzOzdizszN MXnTRW5ITVJ?
KGN MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\zfmlEPTB;Mj62NFM{QSEQvF2= M2DFfHNCVkeHUh?=
ML-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUD0NG5pUUN3ME2yMlY{PTF{IN88US=> NHXibldUSU6JRWK=
LAMA-84 NV;wT5JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TZZmlEPTB;Mj62PVU1PSEQvF2= NILlRmtUSU6JRWK=
LXF-289 NVvNNY1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfRXI5KSzVyPUKuO|I6QDlizszN NFjrPYtUSU6JRWK=
A101D MmXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n3[WlEPTB;Mj63PFMxPCEQvF2= M1HN[XNCVkeHUh?=
KY821 NX7jenJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDTTWM2OD1{Lke5O|U5KM7:TR?= M1HueXNCVkeHUh?=
ES4 M3TUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPZO|NpUUN3ME2yMlgxPjJ6IN88US=> NH74OpJUSU6JRWK=
SCC-3 M4nLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjWcHBKSzVyPUKuPFI5QTFizszN MYfTRW5ITVJ?
NALM-6 NV;GNIo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwOUC0O|Mh|ryP NXLjPZFnW0GQR1XS
BL-41 NHrzT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnxNHdKSzVyPUKuPVEzOjJizszN NFfnT|NUSU6JRWK=
OPM-2 NUfSTWRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnoXJJKSzVyPUOuNFU6PTRizszN MlPpV2FPT0WU
SF126 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DrNmlEPTB;Mz6wOlE6QCEQvF2= NYXoT3NbW0GQR1XS
BE-13 NGPMemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHhNZlKSzVyPUOuNlMyOTFizszN M4njV3NCVkeHUh?=
SF268 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTNwM{K4Olkh|ryP NFLQe2tUSU6JRWK=
MOLT-4 M2TpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwM{m4N|gh|ryP NUnrS5hMW0GQR1XS
PF-382 NVTJOplGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNwNES1O{DPxE1? M{K1SHNCVkeHUh?=
HEL Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXKW5lKSzVyPUOuOFgxODVizszN MV3TRW5ITVJ?
RPMI-6666 NGjYdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnRcYdKSzVyPUOuOVQyPzFizszN NHr4NYVUSU6JRWK=
QIMR-WIL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nje2lEPTB;Mz62N|M6OSEQvF2= MULTRW5ITVJ?
ATN-1 M4T0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX21eldKUUN3ME2zMlY4OTF2IN88US=> MmDIV2FPT0WU
BB49-HNC M1j1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjjeIFKSzVyPUOuO|A2ODhizszN NI\WSm9USU6JRWK=
HCE-4 M2O1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe0[lFKSzVyPUOuO|g3PDJizszN MYnTRW5ITVJ?
SK-LMS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwOEOzN|gh|ryP MWHTRW5ITVJ?
MS-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\lTWM2OD1|LkizO|c5KM7:TR?= NXTLSpFTW0GQR1XS
JAR M{jYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzQTWM2OD1|Lkm4PFMzKM7:TR?= MmrYV2FPT0WU
KE-37 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnue3pKSzVyPUSuNFYyPThizszN NUfDOGlLW0GQR1XS
LB996-RCC NVy5V4x2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O5bGlEPTB;ND6xNlE3QCEQvF2= NXfPe|ZWW0GQR1XS
HH M2rzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTWPVJvUUN3ME20MlIxQTF2IN88US=> NWHoOVVlW0GQR1XS
HL-60 NFn0XZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHHRlFuUUN3ME20MlIyODZ3IN88US=> NHXqV2tUSU6JRWK=
HOP-62 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjOXnNMUUN3ME20MlM{PTJizszN MW\TRW5ITVJ?
NOMO-1 M4rZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzaOYE{UUN3ME20MlM{Pjl7IN88US=> NEm4SJJUSU6JRWK=
DU-4475 NYnCbFN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHqTWM2OD12LkO2O|I6KM7:TR?= MmjSV2FPT0WU
LC4-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTRwM{iwO{DPxE1? MY\TRW5ITVJ?
MC116 M37XN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnhenVKSzVyPUSuOFMxQDFizszN MmW0V2FPT0WU
SW982 NF\wO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO0SXhKSzVyPUSuOVU{ODdizszN NInBZ|dUSU6JRWK=
SK-N-DZ M{jYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjKWZZCUUN3ME20MlY4ODl7IN88US=> NGjD[lNUSU6JRWK=
EW-1 NH;VS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjq[pNKSzVyPUSuOlc6OTFizszN MVHTRW5ITVJ?
SU-DHL-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHJTWM2OD12LkiwNVc1KM7:TR?= M{\yR3NCVkeHUh?=
L-363 M32yOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPSbmtKSzVyPUSuPFA3OjFizszN MoDvV2FPT0WU
OS-RC-2 NUfuUZhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTXbYtwUUN3ME20Mlg4OzFizszN MkHoV2FPT0WU
HD-MY-Z M1qwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTVwMUezNFEh|ryP NYGxVpBCW0GQR1XS
MHH-PREB-1 NH3hWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDrd5NKSzVyPUWuN|I{OTJizszN M4TZNHNCVkeHUh?=
HC-1 M1;XNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnzZ5pbUUN3ME21MlQ{OjlzIN88US=> MnW0V2FPT0WU
SK-MM-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M134SmlEPTB;NT60O|gzKM7:TR?= NHLJemJUSU6JRWK=
SH-4 MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[wTWM2OD13LkS4N|ch|ryP NH65b4RUSU6JRWK=
MHH-CALL-2 MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnPfFVKSzVyPUWuO|Y4OTlizszN MmHEV2FPT0WU
KG-1 NH7sSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2mwXWlEPTB;Nj6wNlg4QCEQvF2= MX\TRW5ITVJ?
J-RT3-T3-5 NFHvW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX4SWJKSzVyPU[uNFc6ODlizszN NED3[nlUSU6JRWK=
MMAC-SF Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfkXI1CUUN3ME22MlExQTR7IN88US=> NYPUOI9PW0GQR1XS
IST-SL2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe3T|Q5UUN3ME22MlEzPTF7IN88US=> MkXzV2FPT0WU
SW954 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzDUo1LUUN3ME22MlI4PTF5IN88US=> NV\NbHVZW0GQR1XS
HDLM-2 Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\yV2RKSzVyPU[uN|IyODlizszN NYPTV2pHW0GQR1XS
ST486 M1HoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPWXpdKSzVyPU[uN|Q4OSEQvF2= M4XHNXNCVkeHUh?=
DG-75 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XmdmlEPTB;Nj60N|A3QSEQvF2= NHO3PHdUSU6JRWK=
EW-3 M1yzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULmW21SUUN3ME22MlQ{OjB5IN88US=> NGCzXJRUSU6JRWK=
8-MG-BA M4jFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfBUZVZUUN3ME22MlUyPTB5IN88US=> MmLwV2FPT0WU
GT3TKB NFPNeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X5cmlEPTB;Nj62NFc3OyEQvF2= NHPoWGdUSU6JRWK=
KU812 NWn0XW9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq1OJlMUUN3ME22MlY6PDJizszN M1zxWXNCVkeHUh?=
CESS M1qzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLGTWM2OD15LkGwOFM5KM7:TR?= M4\FbHNCVkeHUh?=
BC-1 NFfpcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M372SWlEPTB;Nz6yOFgyOiEQvF2= M4XBSHNCVkeHUh?=
MZ1-PC NE\vN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnDO|JKSzVyPUeuN|A{QDlizszN NFe0fm1USU6JRWK=
NCI-H82 NUK3NVZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTdwM{e4OUDPxE1? M2HMfnNCVkeHUh?=
NCI-H1355 NH2wemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XuOmlEPTB;Nz60OVgxPCEQvF2= M2HETnNCVkeHUh?=
RPMI-8226 Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjhRoNKSzVyPUeuOVA4OzlizszN MojnV2FPT0WU
ARH-77 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTdwNUO1PVch|ryP NVf6V2J7W0GQR1XS
MN-60 MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLVTWM2OD15LkW0NFg5KM7:TR?= NGX0R|VUSU6JRWK=
IMR-5 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTdyNUS4O|Yh|ryP M{e2eHNCVkeHUh?=
KARPAS-422 NX7Ed3pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTdwNUeyNFYh|ryP M1rweHNCVkeHUh?=
CA46 M1LMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rZUGlEPTB;Nz61PFAyOiEQvF2= MV\TRW5ITVJ?
SJSA-1 NXnjTYZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTdwNk[wOlEh|ryP NHfEcWpUSU6JRWK=
no-11 M4jkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTdwN{e1OVch|ryP M2H4VXNCVkeHUh?=
IST-SL1 M3TnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPHRpl7UUN3ME24MlAzPDF5IN88US=> NVvLOVl3W0GQR1XS
NCI-H209 M1jzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\rdXRKSzVyPUiuNVE3PTJizszN M1XNZ3NCVkeHUh?=
TALL-1 MnHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LleWlEPTB;OD6xPFM5PCEQvF2= NHLUe5lUSU6JRWK=
KMOE-2 NFO1Z5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRThwMUm0NkDPxE1? MUTTRW5ITVJ?
HCC1599 Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmniTWM2OD16LkG5PVg4KM7:TR?= NG\JOIpUSU6JRWK=
CI-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHxUIU1UUN3ME24MlIxPDFzIN88US=> MV3TRW5ITVJ?
NCI-H1304 NETyV|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:2fWlEPTB;OD6yNFY3OSEQvF2= M3;QfHNCVkeHUh?=
Daudi M2LBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HFcGlEPTB;OD6yN|U1PiEQvF2= NGDm[3BUSU6JRWK=
CPC-N NVyzNnoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LXO2lEPTB;OD6yPVE6QSEQvF2= M{PjfXNCVkeHUh?=
MC-CAR NYCySHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO1TWM2OD16LkOzOVgh|ryP M16wSHNCVkeHUh?=
SW872 NVzUOVRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPNfYRmUUN3ME24MlM1PzV6IN88US=> MorBV2FPT0WU
OVCAR-4 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRThwNUCzOVEh|ryP MmLjV2FPT0WU
OCUB-M MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\1Rld[UUN3ME24MlU3PTB6IN88US=> M1vRVnNCVkeHUh?=
SK-PN-DW MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPyXohLUUN3ME24MlYxQTh3IN88US=> MofqV2FPT0WU
NCCIT NXnTXoFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRThwN{G3OFUh|ryP NF7BbGVUSU6JRWK=
NCI-H1648 NWTuOXhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnxPFd1UUN3ME25MlE{QDN2IN88US=> M3fZSnNCVkeHUh?=
COR-L279 M{fRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTlwM{mwPUDPxE1? MY\TRW5ITVJ?
LS-123 NV7yTJJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrYUHZKSzVyPUmuOlgyPjFizszN Mm\tV2FPT0WU
LP-1 NXvqN5NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHTNWJKSzVyPUmuO|gxQDNizszN M1L5N3NCVkeHUh?=
NB13 NVjMbIR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7veoNKSzVyPUmuO|k6QTRizszN MX3TRW5ITVJ?
ONS-76 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LFbGlEPTB;OT64NVAyPiEQvF2= NGfH[2dUSU6JRWK=
VA-ES-BJ MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTlwOUm5N|Mh|ryP MnTpV2FPT0WU
GR-ST M4G1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSxV21KSzVyPUGwMlIzODdizszN NITwNXJUSU6JRWK=
ES1 NYDONWxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFyLkK5PFQh|ryP NGLmNHdUSU6JRWK=
NB14 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT2OXlJUUN3ME2xNE46Ojd5IN88US=> NUnuNlF2W0GQR1XS
Ramos-2G6-4C10 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\EOmlEPTB;MUGuNlY2KM7:TR?= NXvnOo1bW0GQR1XS
RXF393 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSxTWM2OD1zMT60PFM1KM7:TR?= NXHROGFlW0GQR1XS
NCI-H2107 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzITI97UUN3ME2xNU42QTh2IN88US=> M1HNbHNCVkeHUh?=
K562 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH5TWM2OD1zMT64O|AzKM7:TR?= MXPTRW5ITVJ?
LOUCY NV33fotUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInGR2xKSzVyPUGxMlk5PzVizszN MVnTRW5ITVJ?
TGBC1TKB NGnGfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF{LkCwNkDPxE1? MkLUV2FPT0WU
COLO-320-HSR NGTZSmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL2TWM2OD1zMj6xOVY2KM7:TR?= M1O1SHNCVkeHUh?=
K5 NEfoR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrud2FKSzVyPUGyMlI6QDVizszN MWLTRW5ITVJ?
BC-3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF{LkS2OVEh|ryP M3jYTHNCVkeHUh?=
REH NX3vNWx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf4XnhKSzVyPUGyMlY1QThizszN NV21Zmo2W0GQR1XS
NEC8 M4r1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq0TlNKSzVyPUGyMlY5QDdizszN MYXTRW5ITVJ?
IST-MEL1 NUThXVQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXHcZpKSzVyPUGyMlg3QTRizszN NIrZSplUSU6JRWK=
NCI-H128 NFLPdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDnNXc6UUN3ME2xN{4xPzJ|IN88US=> M2TSdHNCVkeHUh?=
NCI-H1694 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfXSotOUUN3ME2xN{4yOTR2IN88US=> M1TtOHNCVkeHUh?=
TGW MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf0bYdDUUN3ME2xN{4{Ojd4IN88US=> M1nIN3NCVkeHUh?=
NCI-SNU-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrrTXlKSzVyPUGzMlM1PSEQvF2= NWTHWoU4W0GQR1XS
IST-MES1 NX3nbVRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXNTWM2OD1zMz62O|I6KM7:TR?= M33jXnNCVkeHUh?=
CTB-1 NYrkVG1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF|LkeyPVQh|ryP MUnTRW5ITVJ?
HUTU-80 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTF|Lke1O|Mh|ryP NF\DeodUSU6JRWK=
LAN-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF2LkK0OVch|ryP M2HVT3NCVkeHUh?=
KP-N-YS M4OyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\qNGlEPTB;MUSuNlg6PCEQvF2= MXLTRW5ITVJ?
CCRF-CEM NI\ic21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T3N2lEPTB;MUSuOFE3QSEQvF2= M3nSXHNCVkeHUh?=
NCI-H1770 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYniUm9MUUN3ME2xOE42OzZ7IN88US=> NEfE[nRUSU6JRWK=
MZ2-MEL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\PUGlEPTB;MUWuNlI2OSEQvF2= M4izZ3NCVkeHUh?=
COR-L88 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF4LkCwNVIh|ryP M2jsRnNCVkeHUh?=
LOXIMVI NGnRT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETnWIFKSzVyPUG2MlI2PiEQvF2= MmS5V2FPT0WU
KALS-1 M2npXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjBSmo2UUN3ME2xOk42QTNzIN88US=> NXfHW5VQW0GQR1XS
D-283MED MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjlTWM2OD1zNj64OFg6KM7:TR?= M3;xcnNCVkeHUh?=
NCI-H719 NWe5cml[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\xTYhqUUN3ME2xOk46OTZzIN88US=> M2LaOHNCVkeHUh?=
MLMA MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnNbZdYUUN3ME2xOk46QTB5IN88US=> MWXTRW5ITVJ?
EVSA-T NF\mNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16zOWlEPTB;MUeuNFQ5PSEQvF2= MlrhV2FPT0WU
SK-N-FI MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjtOIhKSzVyPUG3MlY6OTNizszN MlL1V2FPT0WU
NTERA-S-cl-D1 NWfNR2N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmzTWM2OD1zNz64OVczKM7:TR?= NWHsPGFkW0GQR1XS
NCI-H1882 NVfIV4pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFqwb5lKSzVyPUG3Mlk5OzRizszN NYL4cIU6W0GQR1XS
A704 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT1TmFKSzVyPUG3Mlk6ODRizszN MkjxV2FPT0WU
L-428 NV7JZ5hiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF6LkCxOVEh|ryP NFHKcI5USU6JRWK=
HCC1187 NH;yUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1izemlEPTB;MUiuNFE5PyEQvF2= MWTTRW5ITVJ?
NCI-H1581 M2T0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF6LkC4OlYh|ryP Mmf4V2FPT0WU
BB65-RCC M4WwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33TU2lEPTB;MUiuOFE3OiEQvF2= NGr6do5USU6JRWK=
EM-2 NHrZXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LydGlEPTB;MUiuOVY4OiEQvF2= NH:wVGhUSU6JRWK=
Raji MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTESYp2UUN3ME2xPU46PTZ3IN88US=> MYDTRW5ITVJ?
TE-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[2dIpKSzVyPUKwMlQyODRizszN NEHKO|VUSU6JRWK=
SW962 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjLTWM2OD1{MD60Nlk{KM7:TR?= NEjw[VVUSU6JRWK=
MHH-NB-11 NHHXfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLXTW5UUUN3ME2yNE42PTJzIN88US=> MoPhV2FPT0WU
no-10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL2TWM2OD1{MT6wNlY1KM7:TR?= M3TJXHNCVkeHUh?=
GDM-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPpO|lKSzVyPUKxMlk1OTRizszN NXWyb256W0GQR1XS
KMS-12-PE NGLjOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS0TWM2OD1{Mj6yO|Qh|ryP NU\GS2lqW0GQR1XS
NCI-H510A M2nNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDGcVdKSzVyPUK0MlEzPzhizszN M{Pvc3NCVkeHUh?=
ES5 NFHUSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC5TWM2OD1{ND63N|Q6KM7:TR?= NHu0dFRUSU6JRWK=
JiyoyeP-2003 NWjicZRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW1XnVKSzVyPUK2MlI4PDJizszN MV3TRW5ITVJ?
NMC-G1 MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfxTIx{UUN3ME2yO{4yQDJ{IN88US=> M3n4WHNCVkeHUh?=
NCI-H446 NEe1[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\HTWM2OD1{Nz60PVQ3KM7:TR?= M3W2eHNCVkeHUh?=
NB7 NEPPXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nPbmlEPTB;MkeuPVIzQSEQvF2= NG\TfmhUSU6JRWK=
A388 Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrmTWM2OD1{OD6wNFc1KM7:TR?= MlzmV2FPT0WU
JVM-2 M2DNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvYVWNKSzVyPUK4MlI5QThizszN Mly2V2FPT0WU
HT-144 NWjVWG13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\RTWM2OD1{OD62PUDPxE1? NWjNOFRyW0GQR1XS
NCI-H747 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\6WZFlUUN3ME2yPE46OTl3IN88US=> M4n6fnNCVkeHUh?=
NCI-H1650 NIHLZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\yb2VXUUN3ME2yPU4xOTd4IN88US=> NIPYXI5USU6JRWK=
EB-3 M1Lqd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTJ7LkWzNFkh|ryP M3TqNnNCVkeHUh?=
KLE MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHq[|VKUUN3ME2yPU43OTlizszN MlXrV2FPT0WU
TK10 NX6zVYVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILLfJhKSzVyPUOwMlEzPiEQvF2= MWXTRW5ITVJ?
COLO-668 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNyLke5NkDPxE1? M1;BcHNCVkeHUh?=
NCI-H23 NIXVXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj3TWM2OD1|MT6xNFY{KM7:TR?= M2XYe3NCVkeHUh?=
GOTO NWLQSFNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTNzLk[wPFUh|ryP M3\2R3NCVkeHUh?=
MSTO-211H M3[5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrzT5l2UUN3ME2zNU45Pjd6IN88US=> MnP5V2FPT0WU
LB831-BLC NGH1fZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjWVldQUUN3ME2zNk4{QDR|IN88US=> Mn\1V2FPT0WU
SCH MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C1[WlEPTB;M{KuPFQ5PSEQvF2= NYHnO4xpW0GQR1XS
EHEB M{\Rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf3TWM2OD1|ND6xNVk{KM7:TR?= NYW0[VQ1W0GQR1XS
U-266 M4Hifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN2LkK3PFEh|ryP NG[4OJFUSU6JRWK=
EW-11 NHjzXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn4SIJKSzVyPUO0MlQ4OjVizszN NFzwSohUSU6JRWK=
TE-9 NXTnNIw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjHS2NKSzVyPUO3MlA1ODFizszN NU\YVINPW0GQR1XS
ES3 NXe3eJNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETVb4hKSzVyPUO3MlUxODRizszN MXLTRW5ITVJ?
NCI-H2141 M2XuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Prc2lEPTB;M{iuNFg1OyEQvF2= M1nHbHNCVkeHUh?=
MPP-89 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjMTWM2OD12Mj6wOVg3KM7:TR?= M{fNN3NCVkeHUh?=
SK-MEL-2 NEH5e2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O5cmlEPTB;NEKuOlQxPSEQvF2= NXTBWY06W0GQR1XS
LC-1F NUfOOY83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTR|LkO2PFIh|ryP MoLQV2FPT0WU
NH-12 MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLTTWM2OD12Mz65N|U6KM7:TR?= NVPPS29XW0GQR1XS
RKO NVm0XlZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTR2LkGyOVIh|ryP NVjKUllTW0GQR1XS
KM-H2 NGrz[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTR2Lkm1O|ch|ryP NF[5fG1USU6JRWK=
SK-UT-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3LWYNKSzVyPUS5Mlg5OjVizszN MXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-ERK / ERK; 

PubMed: 24759734     


Effect of 72 h treatment with sunitinib on SH-SY5Y, SK N BE(2), SK-N-AS and IMR-32 NB cell lines analyzed by Western blot with pSer473Akt, Akt, pThr202/Thr204 Erk1/2 and Erk1/2 antibodies. β-actin was used as a loading control.

p-GSK3β / GSK3β / MYCN ; 

PubMed: 24759734     


Effect of sunitinib on GSK3β phosphorylation and on MYCN total protein in MYCN amplified NB cell lines.

p-STAT3 / STAT3 / p-Src / Src / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 19244102     


Sunitinib reduced Stat3 and Src activity, with no dramatic reduction of AKT, MAPK and JAK signaling in 786-O cells. Tumor cells were treated with sunitinib at indicated concentrations for 2 h (left panels) or 24 h (right panels). Total cell lysates were prepared and western blots were performed using relevant antibodies to detect total protein levels, with β-actin used as the loading control.

24759734 19244102
Growth inhibition assay
Cell viability; 

PubMed: 24369536     


Isolated effects of sunitinib malate on urinary bladder-cancer cell lines viability, assessed by using the MTT assay. The data shown and bars represent the mean values ± SD (SD: standard deviation). *P < 0.05 versus untreated cells.

24369536
In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
+ Expand

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
+ Expand
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01391962 Recruiting Drug: Cediranib|Drug: Sunitinib Sarcoma Alveolar Soft Part National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 19 2011 Phase 2
NCT01073644 Terminated Drug: Sunitinib malate Metastatic Renal Cell Carcinoma Pfizer February 2010 --
NCT00912912 Terminated Drug: Sunitinib Malate Genitourinary Disease M.D. Anderson Cancer Center|Pfizer May 2009 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID